BioCryst selects Swixx BioPharma as commercial partner for ORLADEYO

BioCryst Pharmaceuticals announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO in Central and Eastern Europe, CEE. "We continue to build partnerships with companies that have deep expertise in commercializing rare disease therapies as we advance our mission of bringing ORLADEYO to patients living with hereditary angioedema around the world. The team at Swixx is highly skilled at launching rare disease therapies in Central and Eastern Europe, and we are thrilled to work alongside them to bring our oral, once-daily prophylactic treatment for HAE to patients in this region," said Charlie Gayer, chief commercial officer of BioCryst. Under the terms of the agreement, Swixx will be responsible for commercializing ORLADEYO in 15 markets within CEE.